既往泌尿系肿瘤患者肾移植后肿瘤复发风险的系统综述
系统综述32项回顾性研究共2519例患者(透析1733例,肾移植786例),评估终末期肾病患者既往泌尿系肿瘤经治后肾移植的复发风险。肾细胞癌和前列腺癌的复发、肿瘤特异性及总生存在移植与透析间相似;上尿路尿路上皮癌(尤其马兜铃酸肾病背景)同步双侧肿瘤和复发风险高;睾丸癌数据稀缺。
要点
- 肾移植后免疫抑制不影响低危肾细胞癌和前列腺癌的结局与自然史。
- 上尿路尿路上皮癌在马兜铃酸肾病背景下同步双侧肿瘤和复发风险高。
- 睾丸癌相关数据稀缺,需更多研究以标准化等待期。
核心结论
- 肾移植后免疫抑制不影响低危肾细胞癌和前列腺癌的结局及自然史,因此这些癌症成功治疗至移植的等待时间可缩短。
- 除马兜铃酸肾病这一特殊情况外,因数据匮乏,需更多研究以标准化尿路上皮癌后的等待期。
研究设计与样本
- 系统综述,检索Medline、Embase和Cochrane Library截至2017年3月,纳入报告泌尿系肿瘤患者随后接受移植或维持透析的肿瘤学结局的文献。
- 共纳入32项回顾性研究,2519例患者(透析1733例,肾移植786例)。
- 主要结局为肿瘤复发时间,次要结局包括肿瘤特异生存和总生存,因方法和临床异质性采用叙述性综合,并评估每项纳入研究的偏倚风险。
主要发现
- 肾细胞癌的复发风险、肿瘤特异生存和总生存在移植与透析之间相似。
- 前列腺癌多数肿瘤预后良好,与列线图一致。
- 尿路上皮癌研究主要涉及马兜铃酸肾病背景下的上尿路尿路上皮癌,其同步双侧肿瘤和复发风险高。
- 睾丸癌数据稀缺。
临床怎么用
- 作者认为,对于低危肾细胞癌和前列腺癌成功治疗后至肾移植的等待时间可缩短。
- 作者认为,除马兜铃酸肾病特殊情况外,尿路上皮癌后等待期因数据匮乏需更多研究以标准化。
- 患者摘要指出,需要更可靠证据以推荐标准等待期,尤其针对尿路上皮癌和睾丸癌。
局限性
- 数据异质性高,采用叙述性综合。
- 睾丸癌数据稀缺。
- 尿路上皮癌数据匮乏,需更多研究以标准化等待期。
- 需更可靠证据以推荐标准等待期,尤其针对尿路上皮癌和睾丸癌。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Renal transplantation is the gold standard renal replacement therapy in end-stage renal disease owing to its superior survival and quality of life compared with dialysis. When the potential recipient has a history of cancer, the waiting period before renal transplantation is usually based on the Cincinnati Registry. OBJECTIVE: To systematically review all available evidence on the risk of cancer recurrence in end-stage renal disease patients with a history of urological cancer. EVIDENCE ACQUISITION: Medline, Embase, and the Cochrane Library were searched up to March 2017 for all relevant publications reporting oncologic outcomes of urological cancer in patients who subsequently received a transplantation or remained on dialysis. The primary outcome was time to tumour recurrence. Secondary outcomes included cancer-specific and overall survival. Data were narratively synthesised in light of methodological and clinical heterogeneity. The risk of bias of each included study was assessed. EVIDENCE SYNTHESIS: Thirty-two retrospective studies enrolling 2519 patients (1733 dialysed, 786 renal transplantation) were included. For renal cell carcinomas, the risks of recurrence, cancer-specific, and overall survival were similar between transplantation and dialysis. For prostate cancer, most of the tumours had favourable prognoses consistent with nomograms. Studies dealing with urothelial carcinomas (UCs) mainly included upper urinary tract UC in the context of aristolochic acid nephropathy, for which the risks of synchronous bilateral tumour and recurrence were high. Data on testicular cancer were scarce. CONCLUSIONS: Immunosuppression after renal transplantation does not affect the outcomes and natural history of low-risk renal cell carcinomas and prostate cancer. Therefore, the waiting time from successful treatment for these cancers to transplantation could be reduced. Except in the particular situation of aristolochic acid nephropathy, more studies are needed to standardise the waiting period after UC owing to the paucity of data. PATIENT SUMMARY: Renal transplantation does not appear to increase the risk of recurrence of renal carcinoma or the recurrence of low-risk prostate cancer compared with dialysis. More reliable evidence is required to recommend a standard waiting period especially for urothelial and testicular carcinomas.
引用
- Boissier R, Hevia V, Bruins HM, et al. The Risk of Tumour Recurrence in Patients Undergoing Renal Transplantation for End-stage Renal Disease after Previous Treatment for a Urological Cancer: A Systematic Review. Eur Urol. 2017. PMID: 28803033. doi:10.1016/j.eururo.2017.07.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。